Answers are grounded in this paper and cite their sources.
Boyko AN, Bakhtiyarova KZ, Dudin VA, Zaslavsky LG, Malkova NA, Parshina EV, Fedulov AS, Zinkina-Orikhan AV, Lin’kova YuN, Ivanov RA, Chernovskaya TV. The new pegylated interferon beta-1a (sampeginterferon beta-1a, BCD-054) in the treatment of remitting multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry.
No takes yet. Share an insight, caveat, or question.
Bakhtiyarova et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: